松瑞製藥股份有限公司
松瑞製藥股份有限公司（Savior Lifetec Corporation）開發、生產並供應無菌活性醫藥成份（API）及成品藥。專精於培南類（Carbapenem）抗生素，產品包括亞胺培南（Imipenem）、美羅培南（Meropenem）及厄他培南（Ertapenem）。公司成立於 1993 年，總部位於台灣台南。
今日下跌 5.32%。該股 RSI(6) 為 50.2，處於中性區間，短線無明顯超買超賣訊號。股價站上5日均線，跌破20日、60日、120日均線。短中期均線呈空頭排列，趨勢偏空。KD 指標中性（K=55.2）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-10 | -969 | 0 | +93 | -933 |
| 08-07 | +1,064 | 0 | +147 | +1,120 |
| 08-06 | +22 | 0 | +12 | +18 |
| 08-05 | -167 | 0 | +2 | -191 |
| 08-04 | +102 | 0 | +75 | +126 |
| 08-03 | -286 | 0 | +31 | -273 |
| 07-31 | -363 | 0 | +4 | -366 |
| 07-30 | -499 | 0 | 0 | -569 |
| 07-29 | -765 | 0 | +2 | -782 |
| 07-28 | -1,046 | 0 | +2 | -1,085 |
| 07-27 | +36 | 0 | +36 | +50 |
| 07-24 | +37 | 0 | +12 | +34 |
| 07-23 | -34 | 0 | +10 | -30 |
| 07-22 | -118 | 0 | 0 | -119 |
| 07-21 | +127 | 0 | +2 | +128 |
| 07-20 | +60 | 0 | +1 | +35 |
| 07-17 | -412 | 0 | +48 | -403 |
| 07-16 | +569 | 0 | +44 | +588 |
| 07-15 | +421 | 0 | +17 | +430 |
| 07-14 | +98 | 0 | +2 | +44 |
| 07-13 | +20 | 0 | 0 | 0 |
| 07-09 | +16 | 0 | 0 | +11 |
| 07-08 | +113 | 0 | +31 | +128 |
| 07-07 | +940 | 0 | +39 | +959 |
| 07-06 | +537 | 0 | +57 | +546 |
| 07-03 | +767 | 0 | +26 | +780 |
| 07-02 | -77 | 0 | +2 | -100 |
| 07-01 | +233 | 0 | 0 | +234 |
| 06-30 | +317 | 0 | +2 | +314 |
| 06-29 | +787 | 0 | +33 | +803 |
| 06-26 | -265 | 0 | +2 | -272 |
| 06-25 | +102 | 0 | +2 | +101 |
| 06-24 | +258 | 0 | +1 | +248 |
| 06-23 | -605 | 0 | +18 | -610 |
| 06-22 | -383 | 0 | 0 | -401 |
| 06-18 | +230 | 0 | 0 | +229 |
| 06-17 | -54 | 0 | 0 | -55 |
| 06-16 | -79 | 0 | 0 | -89 |
| 06-15 | -54 | 0 | +2 | -53 |
| 06-12 | +235 | 0 | 0 | +235 |
| 06-11 | -6 | 0 | +1 | -8 |
| 06-10 | +26 | 0 | +16 | +27 |
| 06-09 | +144 | 0 | +12 | +150 |
| 06-08 | +273 | 0 | 0 | +273 |
| 06-05 | +298 | 0 | +36 | +314 |
| 06-04 | +723 | 0 | +68 | +757 |
| 06-03 | +189 | 0 | +1 | +183 |
| 06-02 | +171 | 0 | +10 | +176 |
| 06-01 | +283 | 0 | +42 | +300 |
| 05-29 | +293 | 0 | +107 | +346 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 9569 萬 | +12.1% | -19.4% |
| 2026/03 | 8535 萬 | +32.6% | -9.1% |
| 2026/02 | 6436 萬 | -23.2% | -10.9% |
| 2026/01 | 8386 萬 | -30.0% | -14.2% |
| 2025/12 | 1.20 億 | +36.3% | +106.7% |
| 2025/11 | 8786 萬 | -21.8% | -23.8% |
| 2025/10 | 1.12 億 | +44.3% | +8.2% |
| 2025/09 | 7783 萬 | -18.8% | -39.6% |
| 2025/08 | 9581 萬 | -12.0% | -12.1% |
| 2025/07 | 1.09 億 | +6.2% | +15.1% |
| 2025/06 | 1.02 億 | -10.4% | +13.7% |
| 2025/05 | 1.14 億 | - | -19.9% |